Imsidolimab inhibits the function of the IL-36R, compensating for the deficiency of the endogenous IL-36 regulator in patients with GPP. Imsidolimab has successfully concluded its development program ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
A recent audit of Massachusetts state agencies found that they entered into at least 159 settlements between 2010 and 2022 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback